Pille Harrison

Centre for Economic Policy Research — United Kingdom

Medicine · Health Sciences

26h-index5.6kcitations92works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(25), Rheumatoid Arthritis Research and Therapies(22), Inflammatory Bowel Disease(13), Systemic Lupus Erythematosus Research(13), Lymphoma Diagnosis and Treatment(12)

Publications88 total

#1346 Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed later onset genetic cohort
Nephrology Dialysis Transplantation·2025Open Access
Patient and Carer Feedback on a Nephrology Gene Therapy Study Concept
Journal of the American Society of Nephrology·2025
P138: Impact of Awareness Campaigns on Breast Cancer Diagnosis: A Retrospective Study
The Breast·2025Open Access
Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides (GN)
Journal of the American Society of Nephrology·2022
793 Association of BMI and Radiation Exposure in Coronary Angiography
Heart Lung and Circulation·2020Open Access
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
The Lancet·2018· 202 citedOpen Access
PND2 - RISK OF PARKINSON’S DISEASE (PD) IN PATIENTS TAKING ADRENERGIC DRUG TREATMENTS
Value in Health·2018· 3 cited
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
British Journal of Clinical Pharmacology·2018· 31 citedOpen Access
Post hoc Analyse der Phase 2 FITZROY Studie mit Filgotinib, einem selektiven JAK1 Inhibitor: Einfluss der Krankheitsdauer und -lokalisation auf die klinische Remission in Patienten mit Morbus Crohn
Zeitschrift für Gastroenterologie·2018
SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study
Annals of the Rheumatic Diseases·2018· 1 citedOpen Access
SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis
Annals of the Rheumatic Diseases·2018Open Access
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Arthritis Research & Therapy·2018· 54 citedOpen Access
Additional file 1: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Figshare·2018Open Access
Filgotinib, ein selektiver JAK1-Inhibitor, induziert klinische Remission und Senkung der pSTAT3-Werte in Patienten mit aktivem Morbus Crohn: Ergebnisse der Phase 2 FITZROY Studie
Zeitschrift für Gastroenterologie·2017
OP0229 Effect of baseline serum crp levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies
Annals of the Rheumatic Diseases·2017· 3 citedOpen Access
THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients
Annals of the Rheumatic Diseases·2017· 3 citedOpen Access
THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate
Annals of the Rheumatic Diseases·2017· 1 citedOpen Access
THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients
Annals of the Rheumatic Diseases·2017· 2 citedOpen Access
THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
Annals of the Rheumatic Diseases·2017· 4 citedOpen Access
Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces gut Tissue PSTAT3 in Crohn’s Disease Patients
Gastroenterology·2017· 1 cited
page 1 of 5Next →

Frequent Co-authors

Anne Barton(18), Wendy Thomson(18), Chantal Tasset(18), Stephen Eyre(17), Anne Hinks(17), Lynne J. Hocking(17), Ann W Morgan(17), Jane Worthington(17), Sophia Steer(15), John Bowes(14), Annegret Van der Aa(14), David M. Reid(13), P Wordsworth(12), Anthony G. Wilson(10), Xiayi Ke(9), Paul Emery(8), Edward Flynn(8), Paul Martin(8), René Westhovens(8), Paul Emery(7)